Mumbai, February 16 (Udaipur Kiran): Natco Pharma is currently trading at Rs. 885.35, up by 63.25 points or 7.69% from its previous closing of Rs. 822.10 on the BSE.
The scrip opened at Rs. 825.05 and has touched a high and low of Rs. 895.00 and Rs. 825.05 respectively. So far 382 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1059.60 on 24-Jul-2025 and a 52 week low of Rs. 660.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 895.00 and Rs. 815.05 respectively. The current market cap of the company is Rs. 14724.62 crore.
The promoters holding in the company stood at 49.48%, while Institutions and Non-Institutions held 20.54% and 29.97% respectively.
Natco Pharma has received approval from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March 2026. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
